The dramatic market expansion of GLP-1 medications reflects increased clinical adoption and improved drug availability, which directly impacts formulary coverage, insurance reimbursement patterns, and patient access to these agents in primary care settings. As family physicians become the primary prescribers of GLP-1 therapy for both diabetes and weight management, understanding market dynamics helps clinicians anticipate potential supply chain improvements and negotiate more effectively with payers regarding patient access. The competitive landscape between tirzepatide and semaglutide products creates opportunities to identify which agents will have the most stable supply and coverage in your patient population.
Eli Lilly’s GLP-1 receptor agonist portfolio demonstrated substantial commercial expansion in 2025, with tirzepatide formulations across indications generating significant market uptake. Mounjaro, indicated for type 2 diabetes, achieved 99% year-over-year sales growth, while Zepbound, the obesity indication of the same active pharmaceutical agent, experienced 175% growth. This dual-indication success reflects the widening clinical application of tirzepatide in metabolic disease management and suggests increasing prescriber adoption across both endocrinology and primary care settings managing patients with type 2 diabetes and chronic weight management needs.
The robust sales trajectory indicates market demand continues to expand beyond early adopter phases into broader clinical practice integration. For prescribers, these figures reflect the practical reality that GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists are becoming standard-of-care considerations in type 2 diabetes treatment algorithms and increasingly in obesity management. The differential growth rates between indications suggest Zepbound uptake may be outpacing diabetes applications, which has implications for formulary decisions, insurance coverage patterns, and availability of supply across healthcare systems.
The commercial momentum documented by these sales figures provides context for clinical decision-making regarding tirzepatide’s position within the expanding competitive landscape of incretin-based therapies. Prescribers should consider these market trends alongside clinical evidence when evaluating tirzepatide versus other GLP-1 options for individual patient populations, particularly regarding access, prior authorization requirements, and formulary coverage that may influence real-world prescribing patterns and patient adherence.
Eli Lilly’s GLP-1 medications Mounjaro and Zepbound are seeing rapid market adoption, reflecting strong demand for glucagon-like peptide-1 therapy in both diabetes and weight management populations. This growth indicates increased patient access and clinician familiarity with GLP-1 mechanisms, which may reduce prescribing hesitation in primary care settings. Supply chain improvements and competitive pricing dynamics are likely making these agents more accessible to patients across different insurance tiers. When counseling patients, clarify that market availability does not change individual eligibility criteria, and emphasize that GLP-1 selection should remain based on clinical indication, comorbidities, and patient-specific factors rather than popularity or marketing presence.
“The explosive growth in GLP-1 utilization that we’re seeing across the industry reflects genuine clinical demand from patients who have struggled with weight management and metabolic disease for years, not just market hype. What’s particularly important for my peers to understand is that this expansion of access, while commercially significant, creates an obligation for us as prescribers to be more rigorous about patient selection and metabolic assessment rather than less. I’m counseling my patients upfront that GLP-1 therapy is a tool that works best when combined with behavioral change, not as a replacement for it, and this honest conversation actually improves adherence and long-term outcomes. The real clinical challenge ahead isn’t whether these drugs work, but ensuring we’re identifying which patients will derive meaningful benefit and which might benefit from alternative approaches.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Table of Contents
- FAQ
- What are Mounjaro and Zepbound used for?
- Why are GLP-1 drugs becoming more popular?
- How does a GLP-1 medication work in my body?
- Are there side effects I should know about?
- How long do I need to take a GLP-1 medication?
- Will my insurance cover GLP-1 medications?
- Can I stop taking my diabetes medication once I start a GLP-1?
- How often do I need to take GLP-1 injections?
- What makes GLP-1 drugs different from other weight loss medications?
- Is it safe to use a GLP-1 medication if I don’t have diabetes?
FAQ
What are Mounjaro and Zepbound used for?
Mounjaro is a GLP-1 medication used to treat type 2 diabetes by helping control blood sugar levels. Zepbound is the same medication approved for weight loss in people without diabetes who have obesity or are overweight with weight-related health conditions.
Why are GLP-1 drugs becoming more popular?
GLP-1 drugs have shown strong results in helping people lose weight and control blood sugar, which has increased demand from both patients and healthcare providers. The widespread media coverage and growing availability of these medications have also contributed to their popularity.
How does a GLP-1 medication work in my body?
GLP-1 drugs work by mimicking a hormone your gut naturally produces that helps regulate blood sugar and appetite. They slow down digestion and help you feel fuller longer, which reduces hunger and food intake.
Are there side effects I should know about?
Common side effects include nausea, vomiting, and gastrointestinal upset, especially when starting the medication. Most side effects improve over time as your body adjusts, though some people may need to stop the medication if side effects are severe.
How long do I need to take a GLP-1 medication?
GLP-1 medications work best when taken long term, as weight and blood sugar typically return toward baseline if you stop taking them. Your doctor will discuss with you the appropriate duration based on your individual health goals and response to treatment.
Will my insurance cover GLP-1 medications?
Coverage varies significantly by insurance plan and whether the medication is being used for diabetes or weight loss. You should contact your insurance company directly to understand your specific coverage, copayments, and any prior authorization requirements.
Can I stop taking my diabetes medication once I start a GLP-1?
You should never stop or change your diabetes medications without consulting your doctor first. Your physician may adjust your other medications as your blood sugar improves on GLP-1 therapy, but this requires medical supervision.
How often do I need to take GLP-1 injections?
Most GLP-1 medications are injected once weekly, making them convenient for long-term use. Your doctor will show you how to self-inject and may discuss which formulation is best for your schedule.
What makes GLP-1 drugs different from other weight loss medications?
GLP-1 drugs work through a different mechanism than older weight loss medications and have shown greater effectiveness for both weight loss and metabolic health. They also help control blood sugar, making them beneficial for people with diabetes or prediabetes.
Is it safe to use a GLP-1 medication if I don’t have diabetes?
GLP-1 medications are FDA approved for weight loss in people without diabetes who meet certain weight criteria. However, they should only be used under medical supervision to ensure they are appropriate for your individual health situation and that you receive proper monitoring.
